Protagonist Therapeutics Dividend
Dividend criteriumcontroles 0/6
Protagonist Therapeutics does not have a record of paying a dividend.
Belangrijke informatie
n/a
Dividendrendement
-1.7%
Terugkoop Rendement
Totaal aandeelhoudersrendement | -1.7% |
Toekomstig dividendrendement | n/a |
Dividendgroei | n/a |
Volgende betaaldatum dividend | n/a |
Ex-dividenddatum | n/a |
Dividend per aandeel | n/a |
Uitbetalingsratio | n/a |
Recente dividendupdates
Geen updates
Recent updates
The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey
Oct 16Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't
Apr 13Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise
Feb 25We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Dec 28We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 20An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued
Feb 06We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Protagonist: Too Many Red Flags
Jun 08Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%
May 11Protagonist Is Still Being Undervalued Like There's Real Risk
Feb 01Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates
Aug 06Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year
Jun 19Protagonist Therapeutics closes $132M capital raise
Jun 18Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy
Jun 03This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet
May 21Protagonist EPS beats by $0.03, beats on revenue
May 04Stabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: Insufficient data to determine if PTGX's dividends per share have been stable in the past.
Groeiend dividend: Insufficient data to determine if PTGX's dividend payments have been increasing.
Dividendrendement versus markt
Protagonist Therapeutics Dividendrendement versus markt |
---|
Segment | Dividendrendement |
---|---|
Bedrijf (PTGX) | n/a |
Markt onderkant 25% (US) | 1.5% |
Markt Top 25% (US) | 4.5% |
Gemiddelde industrie (Biotechs) | 2.2% |
Analist prognose (PTGX) (tot 3 jaar) | n/a |
Opmerkelijk dividend: Unable to evaluate PTGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Hoog dividend: Unable to evaluate PTGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Winstuitkering aan aandeelhouders
Verdiendekking: Insufficient data to calculate PTGX's payout ratio to determine if its dividend payments are covered by earnings.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: Unable to calculate sustainability of dividends as PTGX has not reported any payouts.